Komori
Earnings presentation4595MIZUHO MEDY CO.,LTD.Pharmaceuticals

Supplementary Materials for the Fiscal Year Ended December 2025

2025年12月期は売上高が前期比1.5％減、営業利益・経常利益・当期純利益も減益となった。一方、2026年12月期は売上高の小幅増収を見込むものの、研究開発費や人員増強などの費用増により利益は減少する計画。

Worth reading
58In focus
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
232
百万円（2026年12月期営業利益の前期比減少額）
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Earnings presentationFiscal year ending December 202511 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥11,260 million-1.5%
Operating profit¥4,646 million-5.5%
Ordinary income¥4,736 million-8.3%
Net income¥3,425 million-9.2%
Gross Profit Margin69.4%
Operating profit margin41.3%
Selling, general and administrative expenses¥3,172 million
Full-year earnings forecast
Net Sales
¥11,428 million
Gross profit
¥7,888 million
Selling, general and administrative expenses
¥3,474 million
Operating profit
¥4,414 million
Ordinary income
¥4,437 million
Net income for the current fiscal year
¥3,220 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Revenue decline¥-168 million
  • Increase in costs of sales¥-95 million
  • Reduction in personnel expenses¥37 million
  • Increase in R&D expenses¥-36 million
  • Increase in other expenses¥-9 million
  • 営業外収益・費用増減¥-160 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • Assumptions新型コロナ流行規模
    Details年々縮小傾向だが、夏場・冬場の流行は一定数続くと見込む
  • Assumptions感染症全般の年間流行規模・検査需要
    Details過去2～3年と同程度で推移すると見込む
  • 約6億円、12万テスト
    Assumptions新型コロナ遺伝子検査キット
  • 約68億円、970万テスト
    AssumptionsNovel coronavirus antigen test kits
New initiatives
  • 遺伝子POCT機器・試薬システムの新項目開発・次世代システム開発
  • 生産ラインの新設、製造工程の自動化・機械化
  • 迅速マルチ遺伝子POCT検査システムの開発
  • 全社的な人材確保・人員増強
Key KPIsA metric the company considers important as a management benchmark.
  • 遺伝子検査キット販売テスト数160,000 Testing
    Year on year against the same period last year前期320,000テストから減少
  • 抗原キット販売テスト数9,160,000 Testing
    Year on year against the same period last year前期7,080,000テストから増加
  • Smart Gene出荷台数310 Units
    Year on year against the same period last year前期約350台から減少
  • Cumulative Smart Gene units sold5,900 Units
  • Immuno Reader累計販売台数5,500 Units
  • Number of employees193 People
  • Research and development costs¥819 million
    Year on year against the same period last year前期783百万円から増加
Segment results
  • Hospitals and Private Practitioners
    Net Sales¥10,880 million
    Year on year against the same period last yearDown 1.5%
  • OTC and Other
    Net Sales¥380 million
    Year on year against the same period last year0.7%減
Financial targets
ROA・ROE・自己資本比率等の実績推移は示されているが、目標値はNot disclosed
Number of stores and locations
営業拠点は本社、東京、大阪、名古屋、その他各地駐在。期末店舗数・期中の出退店数はNot disclosed
Number of employees
Number of Employees193 People
Record date31 December 2025
Changes during the period and hiring plan製造、販売、管理部門等で人材確保・人員増強を予定
Capital expenditures
¥255 million有形固定資産の取得額
Annual Dividend
2025年12月期 1株当たり100円（中間50円、期末50円）。2026年12月期は予想100円（中間50円、期末50円）
Payout ratio
目標50%。2025年12月期実績55.6%
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredFiscal year ending December 2025
Net Sales¥11,260 million (YoY -1.5%)
Operating profit¥4,646 million (YoY -5.5%)
Ordinary income¥4,736 million (YoY -8.3%)
Net income¥3,425 million (YoY -9.2%)
Gross Profit Margin69.4%
Operating profit margin41.3%
Selling, general and administrative expenses¥3,172 million
Full-year earnings forecastNet Sales ¥11,428 million / Gross profit ¥7,888 million / Selling, general and administrative expenses ¥3,474 million / Operating profit ¥4,414 million / Ordinary income ¥4,437 million / Net income for the current fiscal year ¥3,220 million
Segment resultsSegment Hospitals and Private Practitioners / Net Sales ¥10,880 million / Year on year against the same period last year Down 1.5%, Segment OTC and Other / Net Sales ¥380 million / Year on year against the same period last year 0.7%減
Breakdown of Factors Affecting the ChangeFactors Revenue decline / Amount ¥-168 million, Factors Increase in costs of sales / Amount ¥-95 million, Factors Reduction in personnel expenses / Amount ¥37 million, Factors Increase in R&D expenses / Amount ¥-36 million, Factors Increase in other expenses / Amount ¥-9 million, Factors 営業外収益・費用増減 / Amount ¥-160 million
Key KPIsIndicator name 遺伝子検査キット販売テスト数 / Value 160,000 Testing / Year on year against the same period last year 前期320,000テストから減少, Indicator name 抗原キット販売テスト数 / Value 9,160,000 Testing / Year on year against the same period last year 前期7,080,000テストから増加, Indicator name Smart Gene出荷台数 / Value 310 Units / Year on year against the same period last year 前期約350台から減少, Indicator name Cumulative Smart Gene units sold / Value 5,900 Units / Year on year against the same period last year Not disclosed, Indicator name Immuno Reader累計販売台数 / Value 5,500 Units / Year on year against the same period last year Not disclosed, Indicator name Number of employees / Value 193 People / Year on year against the same period last year Not disclosed, Indicator name Research and development costs / Value ¥819 million / Year on year against the same period last year 前期783百万円から増加
Number of stores and locations営業拠点は本社、東京、大阪、名古屋、その他各地駐在。期末店舗数・期中の出退店数はNot disclosed
Number of employeesNumber of Employees 193 People / Record date 31 December 2025 / Changes during the period and hiring plan 製造、販売、管理部門等で人材確保・人員増強を予定
Assumptions Underlying the Business OutlookAssumptions 新型コロナ流行規模 / Details 年々縮小傾向だが、夏場・冬場の流行は一定数続くと見込む, Assumptions 感染症全般の年間流行規模・検査需要 / Details 過去2～3年と同程度で推移すると見込む, Assumptions 新型コロナ遺伝子検査キット / Value 約6億円、12万テスト, Assumptions Novel coronavirus antigen test kits / Value 約68億円、970万テスト
Financial targetsROA・ROE・自己資本比率等の実績推移は示されているが、目標値はNot disclosed
Annual Dividend2025年12月期 1株当たり100円（中間50円、期末50円）。2026年12月期は予想100円（中間50円、期末50円）
Payout ratio目標50%。2025年12月期実績55.6%
Capital expenditures255 百万円（有形固定資産の取得額）
New initiatives遺伝子POCT機器・試薬システムの新項目開発・次世代システム開発, 生産ラインの新設、製造工程の自動化・機械化, 迅速マルチ遺伝子POCT検査システムの開発, 全社的な人材確保・人員増強
Items this document does not state (10)
Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsRisk amount incorporated into the outlookMedium-term management plan targetsAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

2025年12月期は、新型コロナ検査で遺伝子検査から抗原検査へのシフトが進み、抗原キットの増収が遺伝子検査キットの減収を補ったものの、その他の感染症検査薬が前期流行の反動で減収となった。2026年12月期は、遺伝子POCT機器・試薬システムの開発、生産ライン新設・自動化、人材確保・人員増強を進めるため、利益の減少を見込んでいる。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Materials for the Fiscal Year Ended December 2025 | MIZUHO MEDY CO.,LTD. (4595) timely disclosure | Komori